Downward Trends in Proteomics Deal Making
This article was originally published in Start Up
For more than a year, VCs have backed away from the proteomics tools group--drug companies hadn't signed the expected number and value of deals with them, and it was deal revenues that were, according to most business plans, going to support these start-ups. That pharma and biotech companies have a bigger appetite for products than for platform technology has become a truism. Licensors increasingly are finding that they must offer partners more than a discovery technology platform-either by validating targets and building value before out-licensing, or at least having the biological capability in-house to be a true collaborator.
You may also be interested in...
Less than two months after Genomica announced a change in strategic direction, resulting from disappointing market penetration of its third-party enterprise bioinformatics software, the company agreed to be acquired by Exelixis for $110 million in stock--precisely the amount of cash it was sitting on, making the deal in essence a back-door follow-on offering for Exelixis. The acquirer is therefore getting Genomica's software and technology base for a song, a fact that speaks volumes about the sustainability of a software-based bioinformatics business.
The fact that proteomic diversity is most likely several logs greater than genomic diversity is only one reason why moving from gene expression-based analyses to proteomics-based drug development presents a daunting challenge. The large issues go well beyond protein isolation and characterization: Genomics simply doesn't tell you how proteins function in vivo, and companies are just now beginning to amass and integrate the tools to correlate protein structure and function. In many ways, proteomics heralds the second coming of rational drug design, enabled now by high-throughput tools and the algorithms of computational biology. But whether structure-guided drug development will prove to be efficient or cost-effective remains to be seen.
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.